Literature DB >> 3162827

Philadelphia chromosome-positive acute lymphoblastic leukemia cell lines without classical breakpoint cluster region rearrangement.

L Naumovski1, R Morgan, F Hecht, M P Link, B E Glader, S D Smith.   

Abstract

The Philadelphia (Ph) chromosome translocation which is classically observed in chronic myeloid leukemia (CML) is sporadically found in acute lymphoblastic leukemia (ALL). In CML the translocation breakpoint on chromosome 22 is within the breakpoint cluster region, while in childhood ALL, no detectable change in breakpoint cluster region is routinely observed. In order to investigate the nature of this difference, we have established and characterized two cell lines from a child with Ph positive ALL. The cell lines have retained the cytochemical staining pattern, enzyme activity, monoclonal antibody profile, and immunoglobulin gene rearrangements of the child's malignant cells. The cell lines had the same Ph translocation t(9;22) (q34;q11) as the child's malignant cells along with additional chromosome changes. Southern blot analysis showed that the Ph translocation did not involve the 5.8-kilobase breakpoint cluster region segment characteristically seen in CML. The cell lines reported here will be a valuable resource in ascertaining the biological significance of the Ph translocation seen in ALL.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3162827

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Targeting the Proteasome in Refractory Pediatric Leukemia Cells: Characterization of Effective Cytotoxicity of Carfilzomib.

Authors:  Lucy Swift; Aarthi Jayanthan; Yibing Ruan; Ronald Anderson; Jessica Boklan; Tanya Trippett; Aru Narendran
Journal:  Target Oncol       Date:  2018-12       Impact factor: 4.493

Review 2.  B-cell identity as a metabolic barrier against malignant transformation.

Authors:  Lai N Chan; Markus Müschen
Journal:  Exp Hematol       Date:  2017-06-24       Impact factor: 3.084

3.  Ex vivo activity of cardiac glycosides in acute leukaemia.

Authors:  Helene Hallböök; Jenny Felth; Anna Eriksson; Mårten Fryknäs; Lars Bohlin; Rolf Larsson; Joachim Gullbo
Journal:  PLoS One       Date:  2011-01-05       Impact factor: 3.240

4.  Comparison of effects of the ethanolic extracts of brazilian propolis on human leukemic cells as assessed with the MTT assay.

Authors:  Gilberto C Franchi; Cleber S Moraes; Viviane C Toreti; Andreas Daugsch; Alexandre E Nowill; Yong K Park
Journal:  Evid Based Complement Alternat Med       Date:  2011-09-28       Impact factor: 2.629

5.  DRUG-NEM: Optimizing drug combinations using single-cell perturbation response to account for intratumoral heterogeneity.

Authors:  Benedict Anchang; Kara L Davis; Harris G Fienberg; Brian D Williamson; Sean C Bendall; Loukia G Karacosta; Robert Tibshirani; Garry P Nolan; Sylvia K Plevritis
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-13       Impact factor: 11.205

6.  Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway.

Authors:  L Puil; J Liu; G Gish; G Mbamalu; D Bowtell; P G Pelicci; R Arlinghaus; T Pawson
Journal:  EMBO J       Date:  1994-02-15       Impact factor: 11.598

7.  Gene expression profiling of leukemic cells and primary thymocytes predicts a signature for apoptotic sensitivity to glucocorticoids.

Authors:  Aaron L Miller; Spogmai Komak; M Scott Webb; Edward H Leiter; E Brad Thompson
Journal:  Cancer Cell Int       Date:  2007-11-28       Impact factor: 5.722

Review 8.  Polyphenols as key players for the antileukaemic effects of propolis.

Authors:  Murtala B Abubakar; Wan Zaidah Abdullah; Siti Amrah Sulaiman; Boon Suen Ang
Journal:  Evid Based Complement Alternat Med       Date:  2014-03-19       Impact factor: 2.629

9.  Inhibition of MDM2 by nilotinib contributes to cytotoxicity in both Philadelphia-positive and negative acute lymphoblastic leukemia.

Authors:  Hailong Zhang; Lubing Gu; Tao Liu; Kuang-Yueh Chiang; Muxiang Zhou
Journal:  PLoS One       Date:  2014-06-26       Impact factor: 3.240

10.  KLF5 controls glutathione metabolism to suppress p190-BCR-ABL+ B-cell lymphoblastic leukemia.

Authors:  Cuiping Zhang; Angelo D'Alessandro; Ashley M Wellendorf; Fatima Mohmoud; Juana Serrano-Lopez; John P Perentesis; Kakajan Komurov; Gabriela Alexe; Kimberly Stegmaier; Jeffrey A Whitsett; H Leighton Grimes; Jose A Cancelas
Journal:  Oncotarget       Date:  2018-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.